Advertisement
Advertisement

RNAZ

RNAZ logo

TransCode Therapeutics, Inc. Common Stock

10.57
USD
-0.01
-0.05%
Oct 03, 15:58 UTC -4
Closed
exchange

After-Market

10.57

0.00
0.00%

TransCode Therapeutics, Inc. Common Stock Profile

About

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.

Info & Links

CEO

Thomas A. Fitzgerald

Headquarters

6 Liberty Square, #2382
Boston, MA 02109, UNITED STATES

Sector

Medical

Auditor

WithumSmith+Brown, PC

Share holders

--

Employees

7

TransCode Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

8.82M

Enterprise Value

1.44M

Enterprise Value/EBITDA(ttm)

-0.10

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.43

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-378.30%

Return on Invested Capital(ttm)

-34.43%

Return on Assets(ttm)

-186.01%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-14.34M

Net Income Available to Common(ttm)

-24.63M

Diluted EPS(ttm)

--

Share Statistics

Beta (5Y Monthly)

1.50

52-Week Change

-98.13%

S&P 500 52-Week Change

17.90%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

833.68K

Dividend Yield

0.00%

Float4

834.00K

% Held by Insiders

0.01%

% Held by Institutions

0.00%

Balance Sheet

Total Cash(mrq)

7.37M

Total Cash Per Share(mrq)

8.85

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.27%

Quick Ratio(mrq)

5.27%

Book Value Per Share(mrq)

7.37

Cash Flow

Operating Cash Flow Per Share(ytd)

-8.75

Free Cash Flow(ytd)

-7.29M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement